Analysis of New Drug Registration for Biological
Products from 2010 to 2015 in China

亚洲社会药学

Analysis of New Drug Registration for Biological Products from 2010 to 2015 in China

Liu Dandan1, 2, Chen Yuwen1*

1.School of Business Administration, Shenyang Pharmaceutical University, Shenyang 110016, China; 2.Department of pharmacy, Fujian Health College, Fuzhou 350101, China

出版日期:2017-06-20 发布日期:2017-08-31

Analysis of New Drug Registration for Biological Products from 2010 to 2015 in China

Liu Dandan1, 2, Chen Yuwen1*

1.School of Business Administration, Shenyang Pharmaceutical University, Shenyang 110016, China; 2.Department of pharmacy, Fujian Health College, Fuzhou 350101, China

Online:2017-06-20 Published:2017-08-31
Contact: Chen Yuwen, professor. Major research area: pharmacy administration. Tel: 024-43520303, E-mail: cywwyc@163.com.

摘要/Abstract

摘要： Objective To study the situation of new drug registration for biological products from 2010 to 2015 in China. Methods Information of new drug registration for biological products from 2010 to 2015 in China was collected and classified and development trend was made from several aspects: the total number of new drug registration application, application types, drug types and registration classification. Results and Conclusion New drug research and development of biological products in China showed a trend of rapid growth. At the same time, the innovation level of new drug research and development of biological products was improved. China has made a great achievement in monoclonal antibody research and development.

关键词: biological products, new drug registration, analysis

Abstract: Objective To study the situation of new drug registration for biological products from 2010 to 2015 in China. Methods Information of new drug registration for biological products from 2010 to 2015 in China was collected and classified and development trend was made from several aspects: the total number of new drug registration application, application types, drug types and registration classification. Results and Conclusion New drug research and development of biological products in China showed a trend of rapid growth. At the same time, the innovation level of new drug research and development of biological products was improved. China has made a great achievement in monoclonal antibody research and development.

Key words: biological products, new drug registration, analysis

Liu Dandan, Chen Yuwen. Analysis of New Drug Registration for Biological Products from 2010 to 2015 in China[J]. 亚洲社会药学.

Liu Dandan, Chen Yuwen. Analysis of New Drug Registration for Biological Products from 2010 to 2015 in China[J]. Asina Journal Of Social Pharmacy.

[1]	Han Chengcheng, Dong Li. Study on the Market Environment of Heparin and Development Suggestions in China Based on the PEST Model[J]. 亚洲社会药学, 2025, 20(1): 38-46.
[2]	Li Jingran, Zhang Dawei, Jia Zheng, Xing Hua. Study on the Impact of Digital Economy on Innovation of Pharmaceutical Companies[J]. 亚洲社会药学, 2025, 20(1): 57-67.
[3]	Li Qian, Zhang Wenfeng, Yuan Hongmei. Identification and Prediction of Key Technologies in Ginsenosides Based on Genetic Knowledge Persistence Algorithm[J]. 亚洲社会药学, 2025, 20(1): 68-79.
[4]	Zhang Xuefeng, Jia Zheng, Fu Shuyong, Zhang Dawei, Xing Hua. Research on the Influence of Government R&D Funding and Enterprise R&D Investment on the Innovation Efficiency of Pharmaceutical Industry[J]. 亚洲社会药学, 2024, 19(4): 361-370.
[5]	Fu Nan, Li Qian, Yuan Hongmei. Analysis of Patents Related to COVID-19 - Based on Patent Clustering Model in Specific Fields[J]. 亚洲社会药学, 2024, 19(4): 371-382.
[6]	Liu Baijun, Fang Tingxiu, Liu Yue, Yuan Hongmei. Development Trend and Prediction of Stem Cell Technology in China from the Perspective of Patent [J]. 亚洲社会药学, 2024, 19(3): 251-262.
[7]	Ren Hongyan, Wang Yaoling, Hui Xu, Li Xue, Zhao Kun, Huang Zhe. Meta-analysis of Cohort Studies on Clinical Efficacy of Icodextrin Peritoneal Dialysate [J]. 亚洲社会药学, 2024, 19(3): 279-290.
[8]	Liu Yue, Zeng Yingying, Li Xue, Yuan Hongmei. Analysis of Technical Intelligence of Tumor Cell Therapy Based on Patent Map[J]. 亚洲社会药学, 2024, 19(2): 191-201.
[9]	Du Peng, Huang Zhe, Dong Li. Game Analysis of Regulation for Online Prescription Drugs under Customer Feedback Mechanism[J]. 亚洲社会药学, 2024, 19(2): 147-158.
[10]	Qu Simeng, Wang Shuling. Comparative Analysis of Profit Model of Typical Pharmaceutical O2O Enterprises in China[J]. 亚洲社会药学, 2024, 19(1): 81-88.
[11]	Wang Yuejun, Yang Yue, Huang Zhe. Research on Incentive Policies for Chinese Innovative Drug R&D - Taking Innovative Anti-tumor Drugs as an Example[J]. 亚洲社会药学, 2023, 18(4): 303-314.
[12]	Xiu Yu, Wang Shuling. Investigation and Countermeasures of the Development of Chinese Pharmaceutical E-commerce in the B2C Model Based on PEST-SWOT Analysis[J]. 亚洲社会药学, 2023, 18(4): 398-405.
[13]	Sun Quan, Zhang Fang, Dong Li. Cost-effectiveness Analysis of Insulin Degludec and Liraglutide Injection in the Treatment of Type 2 Diabetes [J]. 亚洲社会药学, 2023, 18(3): 281-295.
[14]	Li Qiao, Wang Aili, Wu Di, Chen Yuwen. Analysis of Adverse Reactions in the Treatment of COVID-19 with Three Chinese Patent Medicines and Three Herbal Formulas [J]. 亚洲社会药学, 2023, 18(1): 8-16.
[15]	Chen Chuhan, Sun Lihua. Economic Evaluation of Cervical Cancer Prevention Strategies in China [J]. 亚洲社会药学, 2023, 18(1): 57-63.

亚洲社会药学

Analysis of New Drug Registration for Biological Products from 2010 to 2015 in China

Analysis of New Drug Registration for Biological Products from 2010 to 2015 in China

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价